Abstract: A roller ball assembly is provided. The assembly includes a primary roller ball supported by a support element that is composed of a superhard material. The assembly includes a cup defining a cavity within which the support element is positioned. A cap is coupled with the cup and positioned to retain the primary roller ball within the cavity. Also, a cup is disclosed for supporting roller halls. Additionally, disclosed are system and apparatus incorporating the assembly, as well as to methods of making and using the same.

Abstract: The present disclosure relates to aerosol delivery devices, methods of producing such devices, and elements of such devices. In some embodiments, the present disclosure provides devices configured for vaporization of an aerosol precursor composition that is contained in a reservoir and transported to a heating element by a liquid transport element. The liquid transport element may include a porous monolith.

Abstract: Apparatus and methods for extracellular vesicle enrichment are described in which apparatus may be used to create plasma preparations that are enriched in EV-containing fluid sample. Generally, one variation of a method may generally comprise contacting the fluid sample with a plurality of absorbent chromatographic beads to concentrate EVs from the fluid sample, and separating the beads from the fluid sample.

Abstract: A method of measuring while drilling includes positioning at least one sensor downhole; and transmitting sensed data while drilling from the at least one sensor to surface without storing the sensed data downhole and system.

Abstract: At least two substantially purified tumor necrosis factor (TNF) inhibitors are disclosed which are glycoproteins that are active against TNF. The isolation of 3O kDa and 40 KDa TNF inhibitor from urine is disclosed. The deglycosylated form of the 3O kDa TNF inhibitor and 40 kDa TNF inhibitor are described as being active against TNF. The 40 kDa TNF inhibitor is active against both TNF alpha a TNF beta. The amino acid sequence of the 30 kDa TNF inhibitor and the 40 kDa TNF inhibitor are disclosed. Methods for isolating the TNF inhibitors from human U937 cell medium and producing the proteins by recombinant-DNA methods are also described.